Business Description
AN2 Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US0373261058
Total Employee Number:
21Description
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.93 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 22.9 | |||||
3-Year EPS without NRI Growth Rate | 25.4 | |||||
3-Year FCF Growth Rate | 23.2 | |||||
3-Year Book Growth Rate | -26.7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 12.44 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 41.68 | |||||
9-Day RSI | 52.7 | |||||
14-Day RSI | 56.57 | |||||
3-1 Month Momentum % | -1.58 | |||||
6-1 Month Momentum % | 345.71 | |||||
12-1 Month Momentum % | 337.38 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 14.32 | |||||
Quick Ratio | 14.32 | |||||
Cash Ratio | 14.04 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -12.2 | |||||
Shareholder Yield % | -18.01 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -53.35 | |||||
ROA % | -48.47 | |||||
ROIC % | -753.35 | |||||
3-Year ROIIC % | -820.75 | |||||
ROCE % | -57 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 2.86 | |||||
Price-to-Tangible-Book | 2.86 | |||||
EV-to-EBIT | -3.78 | |||||
EV-to-EBITDA | -3.78 | |||||
EV-to-FCF | -4.79 | |||||
| Price-to-Net-Current-Asset-Value | 2.93 | |||||
| Price-to-Net-Cash | 2.99 | |||||
Earnings Yield (Greenblatt) % | -26.46 | |||||
FCF Yield % | -13.62 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ANTX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
AN2 Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.07 | ||
| Beta | -3.0443 | ||
| 3-Year Sharpe Ratio | 0.5 | ||
| 3-Year Sortino Ratio | 1.19 | ||
| Volatility % | 209.73 | ||
| 14-Day RSI | 56.57 | ||
| 14-Day ATR ($) | 0.457952 | ||
| 20-Day SMA ($) | 5.5095 | ||
| 12-1 Month Momentum % | 337.38 | ||
| 52-Week Range ($) | 1 - 7.19 | ||
| Shares Outstanding (Mil) | 37.74 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
AN2 Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
AN2 Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-12 | In 86 days | ||
| Second quarter earnings results for 2026 | 2026-08-11 | 5.91 (+0.00%) | ||
| Guidance call for 2026 | 2026-06-04 12:50 | 4.20 (+2.44%) | ||
| General meeting for 2026 | 2026-06-03 08:00 | 4.07 (-5.13%) | ||
| Guidance call for 2026 | 2026-05-19 16:00 | 4.48 (-5.68%) | ||
| First quarter earnings results for 2026 | 2026-05-11 | 4.46 (-2.83%) | ||
| Annual report for 2025 | 2026-03-17 | 4.69 (-2.70%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-17 | 4.69 (-2.70%) | ||
| Leerink Global Healthcare Conference | 2026-03-10 15:40 | 5.25 (+73.84%) | ||
| AN2 Webcast Event | 2026-03-04 09:30 | 1.06 (+0.00%) |
Show
Entries
AN2 Therapeutics Inc Frequently Asked Questions
What is AN2 Therapeutics Inc(ANTX)'s stock price today?
The current price of ANTX is $5.97. The 52 week high of ANTX is $7.19 and 52 week low is $1.00.
When is next earnings date of AN2 Therapeutics Inc(ANTX)?
The next earnings date of AN2 Therapeutics Inc(ANTX) is 2026-11-12 Est..
Does AN2 Therapeutics Inc(ANTX) pay dividends? If so, how much?
AN2 Therapeutics Inc(ANTX) does not pay dividend.
Guru Commentaries on NAS:ANTX
No articles.
Press Release
Articles on AN2 Therapeutics Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers